Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645172 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAPTBP1GAAGSK3A | |
| SCHEMBL14645173 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2LMNAPTBP1GAAGSK3A | |
| SCHEMBL16492677 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAPTBP1GAAGSK3A | |
| SCHEMBL14645250 | 0.79 | LMNA (0.37) | SMN1; SMN2LMNAPTBP1GAAL3MBTL1 | |
| SCHEMBL14645252 | 0.79 | LMNA (0.37) | SMN1; SMN2LMNAPTBP1GAAL3MBTL1 | |
| SCHEMBL14645253 | 0.79 | LMNA (0.37) | SMN1; SMN2LMNAPTBP1GAAL3MBTL1 | |
| SCHEMBL12444962 | 0.79 | PPARA (0.38) | SMN1; SMN2LMNAPTBP1GAAGSK3A | |
| SCHEMBL14645187 | 0.78 | LMNA (0.50) | SMN1; SMN2LMNAGAAGSK3AGSK3B | |
| SCHEMBL14645185 | 0.78 | LMNA (0.50) | SMN1; SMN2LMNAGAAGSK3AGSK3B | |
| SCHEMBL14645186 | 0.78 | LMNA (0.50) | SMN1; SMN2LMNAGAAGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149541-B2 | Tyrosine ligation process | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729178-A1 | TYROSINE LIGATION PROCESS | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013009564-A1 | TYROSINE LIGATION PROCESS | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141034-A1 | TYROSINE LIGATION PROCESS | ACP1, LTK, TTL | SMN1; SMN2 1539/4885LMNA 623/4885PTBP1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.